EDP Sciences logo
Web of Conferences logo
Search
Menu
All issues Volume 245 (2021) E3S Web Conf., 245 (2021) 03057 References
Open Access
Issue
E3S Web Conf.
Volume 245, 2021
2021 5th International Conference on Advances in Energy, Environment and Chemical Science (AEECS 2021)
Article Number 03057
Number of page(s) 11
Section Chemical Performance Research and Chemical Industry Technology Research and Development
DOI https://doi.org/10.1051/e3sconf/202124503057
Published online 24 March 2021
  1. Hirsch F R, Scagliotti G V, Mulshine J L, Kwon R, Curran W J, Wu Y-L and Paz-Ares L 2017 Lung cancer: current therapies and new targeted treatments The Lancet 389 299–311 [Google Scholar]
  2. Herbst R S, Morgensztern D and Boshoff C 2018 The biology and management of non-small cell lung cancer Nature 553 446–54 [PubMed] [Google Scholar]
  3. Denisenko T V, Budkevich I N and Zhivotovsky B 2018 Cell death-based treatment of lung adenocarcinoma Cell Death Dis 9 117 [Google Scholar]
  4. Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Düwell P, Zeng Y, Schmollinger J C, Schnurr M, Endres S and Rothenfußer S 2015 Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy J Natl Cancer Inst 107 [Google Scholar]
  5. Lantuejoul S, Damotte D, Hofman V and Adam J 2019 Programmed death ligand immunohistochemistry in non-small cell lung carcinoma Journal of thoracic disease 11 S89-s101 [PubMed] [Google Scholar]
  6. Keir M E, Liang S C, Guleria I, Latchman Y E, Qipo A, Albacker L A, Koulmanda M, Freeman G J, Sayegh M H and Sharpe A H 2006 Tissue expression of PD-L1 mediates peripheral T cell tolerance The Journal of experimental medicine 203 883–95 [PubMed] [Google Scholar]
  7. Dong Y, Sun Q and Zhang X 2017 PD-1 and its ligands are important immune checkpoints in cancer Oncotarget 8 2171–86 [PubMed] [Google Scholar]
  8. Bareschino M A, Schettino C, Troiani T, Martinelli E, Morgillo F and Ciardiello F 2007 Erlotinib in cancer treatment Ann Oncol 18 Suppl 6 vi35-41 [PubMed] [Google Scholar]
  9. Ciardiello F and Tortora G 2001 A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clinical cancer research : an official journal of the American Association for Cancer Research 7 2958–70 [PubMed] [Google Scholar]
  10. Manzo A, Montanino A, Carillio G, Costanzo R, Sandomenico C, Normanno N, Piccirillo M C, Daniele G, Perrone F, Rocco G and Morabito A 2017 Angiogenesis Inhibitors in NSCLC Int J Mol Sci 18 [Google Scholar]
  11. Ferrara N 1999 Molecular and biological properties of vascular endothelial growth factor Journal of molecular medicine (Berlin, Germany) 77 527–43 [CrossRef] [PubMed] [Google Scholar]
  12. Ferrara N, Gerber H P and LeCouter J 2003 The biology of VEGF and its receptors Nature medicine 9 669–76 [PubMed] [Google Scholar]
  13. Robinson D R, Wu Y M and Lin S F 2000 The protein tyrosine kinase family of the human genome Oncogene 19 5548–57 [Google Scholar]
  14. Hall R D, Le T M, Haggstrom D E and Gentzler R D 2015 Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC) Translational lung cancer research 4 515–23 [PubMed] [Google Scholar]
  15. Aprile G, Rijavec E, Fontanella C, Rihawi K and Grossi F 2014 Ramucirumab: preclinical research and clinical development Onco Targets Ther 7 1997–2006 [Google Scholar]
  16. Poole R M and Vaidya A 2014 Ramucirumab: first global approval Drugs 74 1047–58 [PubMed] [Google Scholar]
  17. Wu Y L, Cheng Y, Zhou X, Lee K H, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino M R, Pluzanski A, Sbar E I, Wang T, White J L, Nadanaciva S, Sandin R and Mok T S 2017 Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial The Lancet. Oncology 18 1454–66 [PubMed] [Google Scholar]
  18. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez J M, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno M A, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez J L, Sanchez J J, Molina M A, Taron M and Paz-Ares L 2012 Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial The Lancet. Oncology 13 239–46 [CrossRef] [PubMed] [Google Scholar]
  19. Zhou C, Wu Y L, Chen G, Feng J, Liu X Q, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L and You C 2011 Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study The Lancet. Oncology 12 735–42 [CrossRef] [PubMed] [Google Scholar]
  20. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K and Fukuoka M 2010 Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial The Lancet Oncology 11 121–8 [PubMed] [Google Scholar]
  21. Park K, Tan E H, O’Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang J C, Lee K H, Lu S, Shi Y, Kim S W, Laskin J, Kim D W, Arvis C D, Kölbeck K, Laurie S A, Tsai C M, Shahidi M, Kim M, Massey D, Zazulina V and Paz-Ares L 2016 Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial The Lancet. Oncology 17 577–89 [PubMed] [Google Scholar]
  22. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi J H, Lee K Y, Xu C R, Massey D, Kim M, Shi Y and Geater S L 2014 Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial The Lancet. Oncology 15 213–22 [CrossRef] [PubMed] [Google Scholar]
  23. Sequist L V, Yang J C, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater S L, Orlov S, Tsai C M, Boyer M, Su W C, Bennouna J, Kato T, Gorbunova V, Lee K H, Shah R, Massey D, Zazulina V, Shahidi M and Schuler M 2013 Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations J Clin Oncol 31 3327–34 [CrossRef] [PubMed] [Google Scholar]
  24. Soria J C, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K H, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho B C, Cheng Y, Cho E K, Voon P J, Planchard D, Su W C, Gray J E, Lee S M, Hodge R, Marotti M, Rukazenkov Y and Ramalingam S S 2018 Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer N Engl J Med 378 113–25 [Google Scholar]
  25. Nakagawa K, Garon E B, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu C-H, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih J-Y, Au K H, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M, Chu Q, Cortot A, Pujol J-L, Moro-Sibilot D, Fabre E, Lamour C, Bischoff H, Kollmeier J, Reck M, Kimmich M, Engel-Riedel W, Hammerschmidt S, Schütte W, Syrigos K, Ho J C M, Au K-H, Novello S, Ardizzoni A, Pasello G, Gregorc V, Del Conte A, Galetta D, Takahashi T, Nakagawa K, Nishio M, Yoh K, Seto T, Imamura F, Kumagai T, Hotta K, Goto Y, Hosomi Y, Sakai H, Takiguchi Y, Kim Y H, Kurata T, Yamaguchi H, Daga H, Okamoto I, Satouchi M, Ikeda S, Kasahara K, Atagi S, Azuma K, Kumagai T, Aoe K, Kumagai T, Aoe K, Horio Y, Yamamoto N, Tanaka H, Watanabe S, Nogami N, Ozaki T, Koyama R, Hirashima T, Kaneda H, Tomii K, Fujita Y, Seike M, Nishimura N, Kato T, Ichiki M, Saka H, Hirano K, Nakahara Y, Sugawara S, Park K, Kim S-W, Min Y J, Lee H W, Kang J-H, An H J, Lee K H, Kim J-S, Lee G-W, Lee S Y, Alexandru A, Udrea A A, Juan-Vidal Ó, Nadal-Alforja E, Gil-Bazo I, Ponce-Aix S, Paz-Ares L, Rubio-Viqueira B, Alonso Garcia M, Felip Font E, Fuentes Pradera J, Coves Sarto J, Lin M-C, Su W-C, Hsia T-C, Chang G-C, Wei Y-F, Chiu C-H, Shih J-Y, Su J, Cicin I, Goksel T, Harputluoglu H, Ozyilkan O, Henning I, Popat S, Hatcher O, Mileham K, Acoba J, Garon E, Jung G, Raj M, Martin W and Dakhil S 2019 Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet Oncology 20 1655–69 [PubMed] [Google Scholar]
  26. Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K and Maemondo M 2019 Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial The Lancet Oncology 20 625–35 [PubMed] [Google Scholar]
  27. Go R S and Adjei A A 1999 Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J Clin Oncol 17 409–22 [PubMed] [Google Scholar]
  28. Wagstaff A J, Ward A, Benfield P and Heel R C 1989 Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer Drugs 37 162–90 [PubMed] [Google Scholar]
  29. Pinto A L and Lippard S J 1985 Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA Biochimica et biophysica acta 780 167–80 [PubMed] [Google Scholar]
  30. Manohar S and Leung N 2018 Cisplatin nephrotoxicity: a review of the literature Journal of nephrology 31 15–25 [PubMed] [Google Scholar]
  31. Plooy A C, van Dijk M and Lohman P H 1984 Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity Cancer Res 44 2043–51 [Google Scholar]
  32. Zwelling L A, Michaels S, Schwartz H, Dobson P P and Kohn K W 1981 DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard Cancer Res 41 640–9 [Google Scholar]
  33. Hongo A, Seki S, Akiyama K and Kudo T 1994 A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin The International journal of biochemistry 26 1009–16 [PubMed] [Google Scholar]
  34. Sharma S, Ganesh T, Kingston D G and Bane S 2007 Promotion of tubulin assembly by poorly soluble taxol analogs Analytical biochemistry 360 56–62 [PubMed] [Google Scholar]
  35. Karimi M, Bahrami S, Ravari S B, Zangabad P S, Mirshekari H, Bozorgomid M, Shahreza S, Sori M and Hamblin M R 2016 Albumin nanostructures as advanced drug delivery systems Expert opinion on drug delivery 13 1609–23 [PubMed] [Google Scholar]
  36. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M and Soon-Shiong P 2006 Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clinical cancer research : an official journal of the American Association for Cancer Research 12 1317–24 [PubMed] [Google Scholar]
  37. John T A, Vogel S M, Tiruppathi C, Malik A B and Minshall R D 2003 Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer American journal of physiology. Lung cellular and molecular physiology 284 L187-96 [PubMed] [Google Scholar]
  38. Carver L A and Schnitzer J E 2003 Caveolae: mining little caves for new cancer targets Nat Rev Cancer 3 571–81 [Google Scholar]
  39. Simionescu M, Gafencu A and Antohe F 2002 Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey Microscopy research and technique 57 269–88 [PubMed] [Google Scholar]
  40. Minshall R D, Tiruppathi C, Vogel S M and Malik A B 2002 Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function Histochemistry and cell biology 117 105–12 [PubMed] [Google Scholar]
  41. Vogel S M, Minshall R D, Pilipović M, Tiruppathi C and Malik A B 2001 Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein American journal of physiology. Lung cellular and molecular physiology 281 L1512-22 [PubMed] [Google Scholar]
  42. Schnitzer J E and Oh P 1994 Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins The Journal of biological chemistry 269 6072–82 [PubMed] [Google Scholar]
  43. Nyman D W, Campbell K J, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins M J and Von Hoff D D 2005 Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies J Clin Oncol 23 7785–93 [PubMed] [Google Scholar]
  44. Schilling U, Friedrich E A, Sinn H, Schrenk H H, Clorius J H and Maier-Borst W 1992 Design of compounds having enhanced tumour uptake, using serum albumin as a carrier--Part II. In vivo studies International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 19 685–95 [PubMed] [Google Scholar]
  45. Sage H 1986 Culture shock. Selective uptake and rapid release of a novel serum protein by endothelial cells in vitro The Journal of biological chemistry 261 7082–92 [PubMed] [Google Scholar]
  46. Sage H, Johnson C and Bornstein P 1984 Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture The Journal of biological chemistry 259 3993–4007 [PubMed] [Google Scholar]
  47. Gradishar W J 2006 Albumin-bound paclitaxel: a next-generation taxane Expert opinion on pharmacotherapy 7 1041–53 [PubMed] [Google Scholar]
  48. Korman A J, Peggs K S and Allison J P 2006 Checkpoint blockade in cancer immunotherapy Advances in immunology 90 297–339 [CrossRef] [PubMed] [Google Scholar]
  49. Zang X and Allison J P 2007 The B7 family and cancer therapy: costimulation and coinhibition Clinical cancer research : an official journal of the American Association for Cancer Research 13 5271–9 [PubMed] [Google Scholar]
  50. Krummel M F and Allison J P 1995 CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation The Journal of experimental medicine 182 459–65 [CrossRef] [PubMed] [Google Scholar]
  51. Patsoukis N, Wang Q, Strauss L, Boussiotis V A, Patsoukis N, Wang Q, Strauss L and Boussiotis V A 2020 Revisiting the PD-1 pathway Science Advances 6 [Google Scholar]
  52. Ohaegbulam K C, Assal A, Lazar-Molnar E, Yao Y and Zang X 2015 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway Trends in molecular medicine 21 24–33 [PubMed] [Google Scholar]
  53. Dong H, Strome S E, Salomao D R, Tamura H, Hirano F, Flies D B, Roche P C, Lu J, Zhu G, Tamada K, Lennon V A, Celis E and Chen L 2002 Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nature medicine 8 793–800 [CrossRef] [PubMed] [Google Scholar]
  54. Aydin A M, Woldu S L, Hutchinson R C, Boegemann M, Bagrodia A, Lotan Y, Margulis V and Krabbe L M 2017 Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer Onco Targets Ther 10 1487–502 [Google Scholar]
  55. Hellmann M D, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S W, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer J R, O’Byrne K J, Geese W J, Bhagavatheeswaran P, Rabindran S K, Kasinathan R S, Nathan F E and Ramalingam S S 2019 Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer N Engl J Med 381 2020–31 [Google Scholar]
  56. West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter H J, Kopp H-G, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M and Cappuzzo F 2019 Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial The Lancet Oncology 20 924–37 [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.